Ta strona używa pliki cookies, w celu polepszenia użyteczności i funkcjonalności oraz w celach statystycznych. Dowiedz się więcej w Polityce prywatności.
Korzystając ze strony wyrażasz zgodę na używanie plików cookies, zgodnie z aktualnymi ustawieniami przeglądarki.
Akceptuję wykorzystanie plików cookies
Dermatology Review
facebook
eISSN: 2084-9893
ISSN: 0033-2526
Dermatology Review/Przegląd Dermatologiczny
Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

without publication fees
5/2024
vol. 111
 
Share:
Send email
Share:
abstract:
Review article

Dapson in the Treatment of Pyoderma Gangrenosum: a Narrative Review

Paweł Głuszak
1
,
Jacek Beutler
2
,
Nina Kurkowska
2
,
Adriana Polańska
1
,
Ryszard Żaba
3
,
Aleksandra Dańczak-Pazdrowska
1

  1. Department of Dermatology, Poznan University of Medical Sciences, Poznan, Poland
  2. Faculty of Medicine, Poznan University of Medical Sciences, Poznan, Poland
  3. Department of Dermatology and Venereology, Poznan University of Medical Sciences, Poznan, Poland
Dermatol Rev/Przegl Dermatol 2024, 111, 347-357
DOI: https://doi.org/10.5114/dr.2024.148574
Online publish date: 2025/02/25
View full text Get citation
 
PlumX metrics:
Pyoderma gangrenosum is a rare but highly debilitating dermatologic condition frequently associated with systemic disorders such as inflammatory bowel disease and rheumatoid arthritis. The clinical management of pyoderma gangrenosum is particularly challenging due to the absence of standardized diagnostic criteria and evidence-based treatment protocols, which complicates therapeutic decision-making. Dapsone, an anti-inflammatory and immunomodulatory agent, has demonstrated potential therapeutic efficacy in pyoderma gangrenosum by modulating neutrophilic activity, a key factor in the pathogenesis of this disease. This review endeavours to provide a comprehensive synthesis of clinical evidence regarding the application of dapsone in pyoderma gangrenosum management, particularly in scenarios where first-line therapies, such as glucocorticosteroids or biological agents, are contraindicated or inaccessible. Moreover, the review offers practical insights for the integration of dapsone into clinical practice.
keywords:

dapsone, pyoderma gangrenosum, sulphone, neutrophilic dermatosis


Indeks osobowy
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2025 Termedia Sp. z o.o.
Developed by Bentus.